Aldeyra Therapeutics
Immunomodulatory therapies for immune-mediated ocular and systemic diseases
Listed on cro.directory
Biopharmaceutical company developing immunomodulatory therapies for immune-mediated ocular and systemic diseases, with late-stage clinical candidates targeting dry eye disease, allergic conjunctivitis, and retinal conditions.
Phases
Indications / Therapeutic Areas
Services
Modalities
About this organization
Overview
Aldeyra Therapeutics is a biotechnology company devoted to discovering and developing innovative therapies for immune-mediated diseases. The company's approach focuses on modulating protein systems rather than directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways simultaneously while minimizing toxicity.
Product Pipeline
The company's portfolio includes:
- RASP (Reactive Aldehyde Species) Modulators: ADX-248, ADX-246, and chemically related molecules for systemic and retinal immune-mediated diseases
- Reproxalap: A late-stage RASP modulator candidate for dry eye disease and allergic conjunctivitis
- ADX-2191: A novel intravitreal methotrexate formulation for primary vitreoretinal lymphoma and retinitis pigmentosa
Therapeutic Focus
Aldeyra's development strategy targets immune-mediated conditions not adequately addressed by current treatments, with particular emphasis on ocular and systemic inflammatory diseases. The company advances multiple ongoing clinical trials toward commercialization of next-generation medicines.
Submit a verified review for this organization.
Markdown mirror: /companies/aldeyra.md